Transforming cancer care through collaborative research
Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer
Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
Disappointing results from immune checkpoint inhibition combined with androgen deprivation therapy in prostate cancer
Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease
Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery
A study reveals the clonal heterogeneity of de novo metastatic castration-sensitive prostate cancer
Findings suggest that analysis of multiple prostate diagnostic biopsy cores, in contrast to frequent practice, may help reduce tumour mischaracterisation and identify genetic alterations relevant to personalised treatment
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Adjuvant immunotherapy does not improve disease-free survival in renal cell carcinoma
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?
The CXCR2 antagonist AZD5069 plus enzalutamide is shown to be active in mCRPC
In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy
Practice-changing treatments in GU cancers continue to evolve
Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi